Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules Jie Wang, PhD, Shilpa Shivakumar, MD, Kristi Barker,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection.

Erratum Journal of Thoracic Oncology

Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non–Small Cell Lung Cancer Patients

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma Daniel L. Albertus, BS, Christopher.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

Trends in Subpopulations at High Risk for Lung Cancer

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data.

Oncological Characteristics of Radiological Invasive Adenocarcinoma with Additional Ground-Glass Nodules on Initial Thin-Section Computed Tomography:

Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma So Hee Song, MD, Hyunjin Park, PhD, Geewon Lee, MD,

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Go on-pump or off-pump in diabetic patients?

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

MicroRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer Riccardo Cazzoli, PhD, Fiamma Buttitta,

Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter.

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Case-Control Study: Smoking History Affects the Production of Tumor Antigen–Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with.

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype Ting Ye, MD, PhD, Lin Deng, MD, Shengping Wang,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Mitotic Inhibitors Journal of Thoracic Oncology

A Primer on Health Economic Evaluations in Thoracic Oncology

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Jennifer S. Temel, MD, William F. Pirl, MD, Christopher J

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

M. Kusumoto Journal of Thoracic Oncology

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

European Lung Cancer Conference (ELCC) 2016 Organisation

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Journal of Thoracic Oncology

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules Jie Wang, PhD, Shilpa Shivakumar, MD, Kristi Barker, MS, Yanyang Tang, BS, Garrick Wallstrom, PhD, Jin G. Park, PhD, Jun-Chieh J. Tsay, MD, MS, Harvey I. Pass, MD, William N. Rom, MD, Joshua LaBaer, MD, PhD, Ji Qiu, PhD Journal of Thoracic Oncology Volume 11, Issue 3, Pages 334-345 (March 2016) DOI: 10.1016/j.jtho.2015.11.011 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Study design. Journal of Thoracic Oncology 2016 11, 334-345DOI: (10.1016/j.jtho.2015.11.011) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Summary of lung cancer–associated antigens discovered from protein array screening. (A) GO enrichment analysis of lung cancer–associated autoantibody targets selected from protein array screening. Term embryonic morphogenesis has 12 genes, whereas the rest of the node has three or four genes each. (B) Heatmap of differential autoantibody responses in lung cancer compared with in smoker controls. Journal of Thoracic Oncology 2016 11, 334-345DOI: (10.1016/j.jtho.2015.11.011) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Responses of individual autoantibodies from panel II. Individual cutoffs at the 98th percentile values of benign controls were drawn as solid lines. Journal of Thoracic Oncology 2016 11, 334-345DOI: (10.1016/j.jtho.2015.11.011) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Multivariate analysis of clinical factors and autoantibody (AAb) responses. (A) Analysis of smoking history, AAb responses, and nodule size in patients with lung cancer and benign controls. (B) Analysis of smoking history, stage, and AAb responses in patients with lung cancer. (In A and B, smoking is measured by pack-year on the vertical axis. Nodule size is presented by circle diameter.) Journal of Thoracic Oncology 2016 11, 334-345DOI: (10.1016/j.jtho.2015.11.011) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Level of messenger RNA expression of autoantibody targets from both panels (The Cancer Genome Atlas). Only messenger RNA levels in lung adenocarcinoma (ADC) and normal solid tissue (Normal) were graphed. Journal of Thoracic Oncology 2016 11, 334-345DOI: (10.1016/j.jtho.2015.11.011) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions